During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking – for the fourth quarter of 2010. Our data comes from Elsevier's Strategic Transactions.
Amanda Micklus, Maureen Riordan and Theresa Surprenant